From hypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe. A small or a major step? A position paper from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology

被引:7
|
作者
Cardim, Nuno [1 ]
Freitas, Antonio [2 ]
Brito, Dulce [3 ]
机构
[1] Univ Nova Lisboa, Serv Cardiol, Hosp Luz, Fac Ciencias Med, P-1200 Lisbon, Portugal
[2] Hosp Fernando da Fonseca, Serv Cardiol, Amadora, Portugal
[3] Univ Lisbon, Serv Cardiol, Hosp Santa Maria, Fac Med, P-1699 Lisbon, Portugal
关键词
Inherited cardiovascular diseases; Inherited cardiovascular disease centers; Hypertrophic cardiomyopathy; Hypertrophic cardiomyopathy centers; DEATH;
D O I
10.1016/j.repc.2011.09.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence, complexity, clinical importance, heterogeneity and unpredictability of inherited cardiovascular diseases make the development of inherited cardiovascular disease centers an inevitability, with the ultimate goal of reducing the morbidity and mortality associated with these conditions. An inherited cardiovascular disease center may be seen as a subunit of a cardiology department, with health professionals specializing in these types of disorders, organized to provide excellence in all related areas, including diagnosis, treatment, follow-up, prevention, risk stratification and prognosis. Among its objectives are the development of action protocols and the creation of databases that enable patients to be included in national and international research networks. To achieve these objectives these centers should include functional units of clinical and basic sciences, research, training and education, acting in harmony in a holistic approach to patients and their families. As most experience on inherited cardiovascular diseases is based on hypertrophic cardiomyopathy and on "hypertrophic cardiomyopathy centers", these centers represent an excellent opportunity to learn how to set up inherited cardiovascular disease centers. European centers will differ from country to country, reflecting the heterogeneity of national health systems, but will share a common core, presented in this document. Though we are aware that this ambitious project is not at all easy and may be difficult to implement in its entirety - in fact we consider it a major step - our position is that all the efforts to achieve it are worthwhile, considering that the main goal will always be the well-being of those affected by these particular disorders. (C) 2011 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:829 / 835
页数:7
相关论文
共 1 条
  • [1] Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)
    de Boer, Rudolf A.
    Heymans, Stephane
    Backs, Johannes
    Carrier, Lucie
    Coats, Andrew J. S.
    Dimmeler, Stefanie
    Eschenhagen, Thomas
    Filippatos, Gerasimos
    Gepstein, Lior
    Hulot, Jean-Sebastien
    Knoll, Ralph
    Kupatt, Christian
    Linke, Wolfgang A.
    Seidman, Christine E.
    Tocchetti, C. Gabriele
    van der Velden, Jolanda
    Walsh, Roddy
    Seferovic, Petar M.
    Thum, Thomas
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (03) : 406 - 420